How should cefalexin (Keflex) be dosed for treating a urinary tract infection in a patient with end‑stage renal disease?

Cephalexin (Keflex) Dosing for UTI in ESRD

Cephalexin is not an optimal choice for treating UTIs in patients with end-stage renal disease (ESRD), but if used, dose 250-500 mg every 12-24 hours after dialysis on dialysis days, with careful monitoring for clinical response.

Key Considerations for ESRD Patients

Why Cephalexin is Suboptimal in ESRD

• Cephalexin is less well-studied for UTI treatment compared to fluoroquinolones, trimethoprim-sulfamethoxazole, and other agents, and should be used with caution even in patients with normal renal function 1.
• β-lactam agents generally have inferior efficacy and more adverse effects compared to other UTI antimicrobials 1.
• For pyelonephritis specifically, oral β-lactam agents are less effective than other available agents, and if used, should be accompanied by an initial intravenous dose of a long-acting parenteral antimicrobial such as ceftriaxone 1g 1.

Renal Dosing Adjustments

The FDA label does not provide specific ESRD dosing, stating only that "cephalexin should be administered with caution in the presence of markedly impaired renal function" and that "safe dosage may be lower than that usually recommended" 2.

Based on pharmacokinetic studies:

• In anephric patients, single doses of 250-500 mg result in high, prolonged serum concentrations with peak levels usually within 1 hour 3.
• Hemodialysis removes approximately 58% of cephalexin over 6 hours 3.
• The serum half-life increases dramatically from 1.03 hours in normal subjects to theoretically 8.47 hours in patients with creatinine clearance of 0 mL/min 4.
• Patients with creatinine clearance less than 30 mL/min require dosage reduction proportional to their reduced renal function 5.

Practical Dosing Recommendations

For ESRD patients on hemodialysis:

• Administer 250-500 mg after each dialysis session (typically 3 times per week) 1, 3.
• This approach facilitates directly observed therapy and avoids premature drug removal 1.
• The usual adult dose of 250 mg every 6 hours or 500 mg every 12 hours must be significantly modified 2.

For ESRD patients not on dialysis:

• Consider 250-500 mg every 24 hours given the markedly prolonged half-life 4, 5.
• Monitor clinical response closely as data are limited 2.

Alternative Agents to Consider

Better-studied options for UTI in ESRD include:

• Fluoroquinolones (if local resistance <10%): Ciprofloxacin requires dose adjustment (500 mg loading dose, then 250 mg every 48 hours for CrCl <50 mL/min) 1.
• Trimethoprim-sulfamethoxazole: Reduce to half dose for CrCl 15-30 mL/min, or use alternative agent for CrCl <15 mL/min 1.
• Nitrofurantoin is generally preferred for uncomplicated cystitis in patients with adequate renal function, but is contraindicated in ESRD due to inadequate urinary concentrations 1.

Critical Pitfalls

• Do not use standard dosing intervals (every 6 hours) in ESRD patients, as this will lead to dangerous drug accumulation 4, 5.
• Obtain urine culture and susceptibility testing before initiating therapy, as empiric β-lactam use is less reliable than guideline-endorsed agents 1.
• Monitor for treatment failure closely, as β-lactams have lower cure rates for UTIs compared to fluoroquinolones and TMP-SMX 1.
• For pyelonephritis requiring hospitalization, use intravenous agents (fluoroquinolone, aminoglycoside, extended-spectrum cephalosporin, or carbapenem) rather than oral cephalexin 1.

Duration of Therapy

• Uncomplicated cystitis: 7-14 days 2.
• Pyelonephritis with β-lactam: 10-14 days 1.
• Recent evidence suggests twice-daily dosing may be as effective as four-times-daily dosing for uncomplicated UTI in patients with normal renal function, but this has not been studied in ESRD 6, 7.